Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardiovascular biomaterials]

D Loisance1

  • 1Service de Chirurgie Thoracique et Cardiovasculaire, Centre de Recherches Chirurgicales Henri Mondor, CNRS URA 1431, Créteil.

Bulletin De L'Academie Nationale De Medecine
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diseases of the circulatory system: mechanical assistance.

Technology and health care : official journal of the European Society for Engineering and Medicine·2014
Same author

Bridge to transplantation using paracorporeal biventricular assist devices or the syncardia temporary total artificial heart: is there a difference?

The Journal of cardiovascular surgery·2014
Same author

[Four years of circulatory support with the INCOR axial pump from Berlin Heart].

Archives des maladies du coeur et des vaisseaux·2008
Same author

B-type natriuretic peptide to assess haemodynamic status after cardiac surgery.

British journal of anaesthesia·2006
Same author

Embolic and bleeding events after modified Bentall procedure in selected patients.

Heart (British Cardiac Society)·2006
Same author

[Blood activation during long-term mechanical circulatory support].

Pathologie-biologie·2005
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Biomaterials are crucial for artificial organs and therapies, but all cause adverse biological reactions. Understanding these foreign body reactions is key to improving medical device development and safety.

Area of Science:

  • Biomaterials Science
  • Biomedical Engineering
  • Immunology

Context:

  • Hemocompatible biomaterials are essential for medical devices like prostheses and artificial organs.
  • Current biomaterials, despite diverse origins and properties, elicit adverse biological responses.
  • Substitutive therapies utilizing biomaterials are a growing part of healthcare.

Purpose:

  • To explore the mechanisms behind adverse biological reactions to biomaterials.
  • To address the challenges hindering further development and market presence of biomaterials.

Summary:

  • Biomaterials are used in various medical applications, but none are ideal, causing foreign body reactions, coagulation, and inflammation.
  • Historically, biomaterial development relied on empirical methods due to poor understanding of these reactions.

Related Experiment Videos

  • Advances in cellular and molecular biology now offer better insights into these mechanisms.

    • Impact:

    • Improved understanding of biomaterial-induced reactions can lead to safer and more effective medical devices.
    • Addressing liability concerns is critical for continued innovation and availability of essential biomaterials.
    • Enhanced hemocompatibility and reduced adverse reactions will improve patient outcomes in substitutive therapies.